Article Per Year (5 Year)
p-Index From 2020 - 2025
7.962
P-Index
This Author published in this journals
All Journal Jambi Medical Journal : Jurnal Kedokteran dan Kesehatan Jurnal Ilmu Kedokteran (Journal of Medical Science) Jurnal Kesehatan Andalas Global Medical and Health Communication Biomedical Journal of Indonesia Jurnal Profesi Medika: Jurnal Kedokteran dan Kesehatan Jurnal Penelitian Pendidikan IPA (JPPIPA) Window of Health : Jurnal Kesehatan Majalah Kedokteran Andalas Majalah Patologi Indonesia Bioscientia Medicina : Journal of Biomedicine and Translational Research Majalah Kedokteran Neurosains Human Care Journal Indonesian Journal of Clinical Pathology and Medical Laboratory (IJCPML) Jurnal Ners Science Midwifery Nusantara Hasana Journal Bioscientia Medicina : Journal of Biomedicine and Translational Research Cermin Dunia Kedokteran Jurnal Ilmu Kesehatan Indonesia (JIKSI) Neurona
Yuliarni Syafrita
Department Of Neurology, Faculty Of Medicine, Universitas Andalas, Padang, Indonesia.
Agriculture, Biological Sciences & Forestry Humanities Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Dentistry Economics, Econometrics & Finance Education Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Nursing Physics Public Health Veterinary

Published : 73 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 73 Documents
Search

 4   5   6   7   8 
Relationship between Serum p-Tau Levels and Impaired Cognitive Function in Type 2 Diabetes Mellitus Isnu Lucky Riandini; Yuliarni Syafrita; Restu Susanti; Syarif Indra; Lydia Susanti; Fanny Adhy Putri; Reno Bestari
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 8 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i8.1041

Abstract

Background: Type 2 diabetes mellitus (Type 2 DM) is a metabolic disease that causes a global crisis that threatens health and the world economy. Impaired cognitive function is a key factor in reducing health-related quality of life in type 2 DM patients. Phosphorylated Tau (p-Tau) is a microtubule protein that functions in cell signaling, synaptic plasticity, and regulation of genome stability. A malfunction of p-Tau will cause disruption of cell signaling, which can result in impaired cognitive function. This study aims to assess the relationship between serum p-Tau levels and impaired cognitive function in type 2 diabetes mellitus patients. Methods: This research is an observational study, comparative analysis with a cross-sectional design with a sample of 60 type 2 diabetes mellitus patients who sought treatment at the endocrine polyclinic at Dr. M. Djamil General Hospital Padang. Cognitive function was assessed using MoCa-Ina. Serum p-Tau levels were measured using the ELISA method. Data analysis was carried out using SPSS. Results: The average serum p-Tau level in type 2 diabetes mellitus patients with impaired cognitive function was 542.9 pg/ml. The cut-off point for serum p-Tau levels which is associated with impaired cognitive function in type 2 diabetes mellitus patients is 517.2 pg/ml. There was a significant relationship between serum p-Tau levels and impaired cognitive function in type 2 diabetes mellitus patients (p=0.039). Conclusion: There is a significant relationship between serum p-Tau levels and impaired cognitive function in type 2 diabetes mellitus patients.
Study Analysis of Serum Phosphorylated Tau (P-Tau) Levels with Severity and Outcome in Traumatic Brain Injury Patients: A Single Center Observational Study at Dr. M. Djamil General Hospital, Padang, Indonesia Istiqomah; Yuliarni Syafrita; Fanny Adhy Putri; Syarif Indra; Restu Susanti; Reno Bestari
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 9 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i9.1060

Abstract

Background: Traumatic brain injury (TBI) is a global health problem that can cause death and disability in people of productive age. The diagnosis and assessment of TBI severity currently still rely on clinical examination and neuroimaging. However, limited access and cost of neuroimaging are obstacles in many health facilities. Therefore, blood-based biomarkers are needed that can help the diagnosis and prognosis of TBI. Phosphorylated Tau (p-tau) is a potential biomarker that can be measured in serum. This study aims to assess the relationship between serum p-tau levels and severity and outcome in TBI patients. Methods: This research is a comparative study with a cross-sectional design involving 70 TBI patients who came to the emergency room (ER) of Dr. M. Djamil General Hospital Padang. TBI severity was assessed using the Glasgow coma scale (GCS) and grouped into mild (GCS 13-15) and moderate to severe (GCS 3-12). Outcomes were assessed using the Glasgow outcome scale (GOS) and grouped into good (GOS 4-5) and poor (GOS 1-3). Serum p-tau levels were measured using the ELISA method. Data analysis was carried out using SPSS. Results: The median serum p-tau level in the mild TBI group was 165.84 ng/L (IQR 126.18-463.85), while in the moderate to severe TBI group, it was 177.68 ng/L (IQR 87.62-591 .93). There was a significant difference between serum p-tau levels in the mild and moderate to severe TBI groups (p=0.029). The median serum p-tau level in the good outcome group was 167.21 ng/L (IQR 87.62-463.85), while in the poor outcome group it was 187.04 ng/L (IQR 137.75-591.93). There was a significant difference between serum p-tau levels in the good and bad outcome groups (p=0.014). Conclusion: Serum p-tau levels have a significant relationship with severity and outcome in TBI patients. Elevated serum p-tau levels are associated with increased severity of TBI and poor outcomes. Further research is needed to confirm these findings and explore the potential of p-tau as a biomarker in TBI management.
Serum High Mobility Group Box 1 (HMGB1) Protein Levels and Cognitive Function in Epilepsy Patients: A Cross-Sectional Study Rahmi Ulfa; Syafrita, Yuliarni; Lydia Susanti
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 2 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i2.1183

Abstract

Background: Epilepsy is a neurological disease with a high incidence rate. Cognitive decline is one of the consequences of recurrent seizures. Neuroinflammation is closely related to the development of epilepsy and cognitive impairment. An increase in the expression and translocation of High Mobility Group Box 1 (HMGB1) from the nucleus to the extracellular space has been observed in epilepsy patients and experimental animal models. This study aimed to investigate the relationship between serum HMGB1 levels and cognitive function in epilepsy patients. Methods: This cross-sectional observational study involved 45 epilepsy patients. Cognitive function was assessed using the Indonesian version of the Montreal Cognitive Assessment (MoCA-Ina), and serum HMGB1 levels were measured using the ELISA technique. The relationship between cognitive function and HMGB1 levels was analyzed using the Kruskal-Wallis test, with a significance level set at p < 0.05. Results: The mean age of the participants was 28.5 years, with a higher proportion of females. The mean serum HMGB1 level was 22.6 ng/ml. No significant relationship was found between serum HMGB1 levels and cognitive function in epilepsy patients (p = 0.188). Conclusion: Serum HMGB1 protein levels were not associated with cognitive function in this sample of epilepsy patients.
ANALISIS KADAR AMILOID BETA PLASMA DENGAN GANGGUAN KOGNITIF PADA DIABETES MELITUS TIPE 2 Syafrita, Yuliarni; Amir, Darwin; Decroli, Eva; Susanti, Restu
Majalah Kedokteran Neurosains Perhimpunan Dokter Spesialis Saraf Indonesia Vol 35 No 1 (2018)
Publisher : PERDOSNI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52386/neurona.v35i1.38

Abstract

   ANALYSIS OF PLASMA LEVELS OF BETA AMYLOID WITH COGNITIVE IMPAIRMENT IN TYPE 2 DIABETES MELLITUSABSTRACTIntroduction: Type 2 diabetes mellitus (T2DM) and Alzheimer’s disease are two kind of neurodegenerative disease that related with age. Patients with DM show a tendency to develop Alzheimer’s disease, but there is no single marker for predicting a DM case will develop into Alzheimer’s disease. Amyloid cascade beta disturbance is one factor involved in the pathogenesis of DM disease as well as in Alzheimer’s disease, and still believed to be the main factor causing Alzheimer’s dementia.Aims: This research was aimed to determine the correlation between beta amyloid plasm level and demographic factors with the occurrence of cognitive dysfunction in type 2 diabetes mellitus patients.Methods: This was a cross-sectional design study on patients with DM in special DM clinic at M Djamil and Ibnu Sina hospital, Padang, between August—October 2016. Cognitive function was examined using the Montreal Cognitive Assessment Indonesian version (MoCA-Ina). Beta amyloid level was measured by enzyme-linked immunosorbent assay (ELISA) technique. Beta amyloid diagnostic ability was analyzed by using receiver operating characteristics (ROC). The correlation between the variables were analyze by using Chi-square, and p value p<0.05 was considered to be significant. To determine the strongest variables which correlated to cognitive dysfunction, logistic regression analysis were performed.Result: 65 subjects included in this study, where cognititve dysfuntion were present in 35 patients (58.3%). There were significant correlation between disease duration and low levels of 42 beta amyloid in plasma (Aβ42) with the occur- rence of cognitive dysfunction. The multivariate analysis showed that the disease duration, followed by low levels of Aβ42 and education level were the variables correlated with cognitive dysfunction.Discussion: There were a correlation between low levels of 42 beta amyloid in plasma with the occurrence of cog- nitive dysfunction in type 2 diabetes mellitus patients.Keywords: Beta amyloid, cognitive impairment, demographic factors, type 2 DMABSTRAKPendahuluan: Penyakit diabetes melitus tipe 2 (DM) dan penyakit Alzheimer adalah dua penyakit neurodegeneratif yang sering berhubungan dengan usia. Pasien dengan DM menunjukkan kecenderungan untuk menderita penyakit Alzheimer, namun belum ada satupun penanda untuk memprediksi kasus DM yang akan berkembang menjadi penyakit Alzheimer. Gangguan kaskade amiloid beta merupakan faktor yang terlibat pada patogenesis penyakit DM maupun pada penyakit Alzheimer, dan sampai sekarang masih dipercaya sebagai faktor utama yang menyebabkan demensia Alzheimer.Tujuan: Mengetahui hubungan kadar amiloid beta plasma dan faktor demografi dengan gangguan fungsi kognitif pada penderita DM.Metode: Penelitian dengan desain potong lintang ini, terhadap pasien DM yang berobat di Poliklinik khusus diabetes RSUP Dr. M Djamil dan RS Islam Ibnu Sina, Padang, pada periode Agustus–Oktober 2016. Penilaian gangguan kognitif menggunakan Montreal Cognitive Assesment versi Indonesia (MoCA-Ina), dinyatakan terganggu jika nilai <26.Kadar amiloid beta diperiksa dengan metode enzyme-linked immunosorbent assay (ELISA) dan kemampuan diagnostik amiloid beta dianalisis dengan receiver operating characteristics (ROC). Hubungan antar variabel diuji dengan Chi- square, dikatakan bermakna bila nilai p≤0,05. Dilakukan analisis regresi logistik untuk menentukan variabel yang paling kuat hubungannya dengan gangguan fungsi kognitif.Hasil: Didapatkan 65 subjek dengan rerata usia 61,62+7,6 tahun dan sebanyak 53,8% mengalami gangguan fungsi kognitif. Didapatkan hubungan yang bermakna antara lama sakit dan rendahnya kadar Aβ42 plasma dengan terjadinya gangguan kognitif. Pada analisis multivariat diketahui bahwa urutan kekuatan variabel yang berhubungan dengan terjadinya gangguan fungsi kognitif adalah lama sakit, rendahnya kadar Aβ42 plasma, dan tingkat pendidikan.Diskusi: Terdapat hubungan antara lama sakit dan rendahnya kadar Aβ42 plasma dengan terjadinya gangguan kognitif pada penderita DM.Kata kunci: Amiloid beta, DM tipe 2, faktor demografi, gangguan kognitif
Analisa Kadar Glutamat pada Penderita Fibrilasi Atrium dengan Gangguan Fungsi Kognitif Syafrita, Yuliarni; Andy, Marfri; Rasyid, Hauda El
Andalas Journal of Health Vol. 9 No. 4 (2020): Online December 2020
Publisher : Faculty of Medicine, Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/jka.v9i4.1571

Abstract

Salah satu permasalahan neurologi yang ditemukan pada penderita fibrilasi atrium (FA) adalah gangguan kognitif. Silent Brain Infarction (SBI) diyakini menjadi salah satu mekanisme utama yang mendasari terjadinya gangguan ini. Sudah dilaporkan juga bahwa hipoksia serebri akan menimbulkan peningkatan kadar glutamat ektraseluler sehingga bersifat neurotoksisitas dan menimbulkan kematian sel. Tujuan: Menganalisis  kadar serum glutamat pada pasien Fibrilasi Atrial (FA) dengan gangguan kognitif.  Metode: Penelitian dengan disain potong lintang dilakukan di Poliklinik Kardiologi dan Neurologi RS DR M Djamil Padang serta Laboratorium Biomed Fakultas Kedokteran Universitas Andalas. Pemeriksaan kadar glutamat serum dilakukan dengan metode Elisa dan pemeriksaan fungsi kognitif dengan test neuropsikologi Montreal Cognitive Assestment versi Indonesia (MoCA-Ina). Perbedaan kadar glutamat serum pada kelompok FA dengan gangguan kognitif dan kelompok FA tanpa gangguan kognitif diuji dengan t test bila distribusi data normal dan test Mann Whitney bila data tidak terdistribusi normal. Hubungan antara kadar glutamat dengan kejadian gangguan kognitif dilakukan dengan uji Chi-square, setelah dicari dulu nilai cut off point untuk kadar glutamat serum. Uji dikatakan bermakna bila nilai p < 0,05. Hasil: Kadar glutamat serum kelompok FA dengan ganggan kognitif lebih tinggi dari kelompok FA tanpa gangguan kognitif. Pasien FA yang mempunyai kadar glutamat tinggi ( > 29,5µMol/L) beresiko mengalami gangguan kognitif 10,2 kali lebih tinggi dari penderita yang mempunyai kadar glutamat normal (< 29,5 µMol). Simpulan: Ada hubungan antara kadar glutamat serum dengan terjadinya gangguan kognitif pada penderita FA.Kata kunci: fibrilasi atrial, fungsi kognitif, glutamat, silent brain infarction
Gambaran Gejala Depresi pada Penderita Parkinson Disease di RSI Ibnu Sina Padang Mubarak, M. Dzaky; Syafrita, Yuliarni; Nurhayati, Nurhayati; Liza, Rini Gusya; Syahrul, Muhammad Zulfadli
Jurnal Ilmu Kesehatan Indonesia Vol. 5 No. 2 (2024): Juni 2024
Publisher : Fakultas Kedokteran, Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/jikesi.v5i2.1153

Abstract

Abstrak Latar Belakang: Penyakit Parkinson merupakan penyakit neurodegeneratif kronik progresif yang ditandai dengan hilangnya sel saraf (neuron) dopaminergik pada bagian substansia nigra. Pada Penyakit Parkinson dapat ditemukan gejala non motorik seperti gejala psikiatri terutama depresi. Depresi pada penderita parkinson memiliki dampak yang sangat besar pada kualitas hidup karena mengakibatkan penurunan kualitas hidup. Objektif: Penelitian ini bertujuan untuk mengetahui karakteristik penderita Penyakit Parkinson, distribusi terjadinya depresi pada parkinson, dan tingkatan depresi yang dialami pada penderita parkinson di RSI Ibnu Sina Padang. Metode: Penelitian ini adalah penelitian deskriptif dengan pendekatan kualitatif metode Cross Sectional dengan kuesioner Beck Depression Inventory. Pengambilan data penelitian berupa data primer dari semua penderita Parkinson yang berobat jalan pada bulan Maret 2023 hingga Mei 2023 di Poli Saraf RSI Ibnu Sina yang memenuhi kriteria dengan jumlah sampel 29 orang. Hasil: Hasil analisis data disajikan dalam bentuk tabel distribusi frekuensi. Hasil penelitian penderita Penyakit Parkinson lebih banyak ditemukan pada kelompok umur lansia dengan jenis kelamin perempuan dan paling banyak sudah tidak bekerja. Sebagian besar masih berstatus kawin dengan lama menderita sakit parkinson mayoritas selama ≥ 5 tahun dan terbanyak didapatkan pada stadium 3 Penyakit Parkinson. Kasimpulan: Mayoritas sebanyak 65,5% mengalami depresi dan paling banyak pada tingkat depresi sedang. Kata kunci: penyakit parkinson; depresi. Abstract Background: Parkinson's Disease is a progressive chronic neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra. In Parkinson's Disease, non-motor symptoms such as psychiatric symptoms, especially depression, can be found. Depression in people with Parkinson's has a very large impact on quality of life because it results in a decrease in quality of life. Objective: This study aims to determine the characteristics of patients with Parkinson's Disease, the distribution of depression in Parkinson's, and the level of depression experienced in patients with Parkinson's at RSI Ibnu Sina Padang. Methods: This research is a descriptive study with a qualitative approach with a cross sectional method using the Beck Depression Inventory questionnaire. Retrieval of research data in the form of primary data from all Parkinson's patients who were on outpatient treatment from March 2023 to May 2023 at the Ibnu Sina Hospital who met the criteria with a sample size of 29 people. Result: The results of this study found that people with Parkinson's Disease were mostly elderly age group, female, and most were not working. Most were still married, had suffered from Parkinson's disease for 5 years and more, and most found in stage 3 Parkinson's Disease. Conclusion: The majority as much as 65.5% experienced depression and most were at moderate levels of depression) Keywords: parkinson's disease; depression
Chemotherapy-Induced Cognitive Impairment and Neuroaxonal Damage: Investigating the Role of Serum Neurofilament Light Chain Husni Minanda Fikri; Syafrita, Yuliarni; Lydia Susanti; Syarif Indra; Restu Susanti; Reno Bestari
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 6 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i6.1319

Abstract

Background: Chemotherapy-induced cognitive impairment (CICI), colloquially termed "chemobrain," represents a significant challenge for cancer survivors, potentially affecting up to 85% of patients undergoing treatment. Diagnosis often relies on neuropsychological testing and imaging, which may lack sensitivity for early detection or reflect chronic changes. Neurofilament light chain (NfL), a neuronal structural protein released into biofluids upon neuroaxonal damage, emerges as a promising biomarker. This study investigated the relationship between serum NfL levels and the degree of cognitive impairment in patients receiving chemotherapy. Methods: An observational, cross-sectional study was conducted involving 50 cancer patients undergoing chemotherapy at Dr. M. Djamil General Hospital Padang between October and December 2024. Cognitive function was assessed using the Montreal Cognitive Assessment Indonesian version (MoCA-Ina), and depression was screened using the Patient Health Questionnaire-9 (PHQ-9). Serum NfL levels were quantified using an Enzyme-Linked Immunosorbent Assay (ELISA) method. The Kruskal-Wallis test was employed to analyze the relationship between serum NfL levels and cognitive function status (normal, mild impairment, moderate-severe impairment). Results: Cognitive impairment (MoCA-Ina assessed) was identified in 41 (82%) of the 50 participants, with 30 (60%) exhibiting mild and 11 (22%) exhibiting moderate to severe impairment. The median serum NfL level across all subjects was 23.44 pg/ml (range: 13.81-68.71 pg/ml). A statistically significant relationship was observed between serum NfL levels and the presence and severity of cognitive impairment (p = 0.02). Median NfL levels progressively increased from the cognitively normal group (18.49 pg/ml) to the mild impairment group (23.5 pg/ml) and the moderate-severe impairment group (24.5 pg/ml). Post-hoc analysis revealed significant differences in NfL levels between the normal group and both the mild (p=0.03) and moderate-severe (p=0.01) impairment groups. Conclusion: This study demonstrated a significant positive association between serum NfL levels and the presence and severity of cognitive impairment in cancer patients undergoing chemotherapy. These findings support the potential utility of serum NfL as an accessible biomarker for detecting chemotherapy-associated neuroaxonal damage and concomitant cognitive decline.
Serum High Mobility Group Box 1 (HMGB1) Protein Levels and Cognitive Function in Epilepsy Patients: A Cross-Sectional Study Rahmi Ulfa; Yuliarni Syafrita; Lydia Susanti
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 2 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i2.1183

Abstract

Background: Epilepsy is a neurological disease with a high incidence rate. Cognitive decline is one of the consequences of recurrent seizures. Neuroinflammation is closely related to the development of epilepsy and cognitive impairment. An increase in the expression and translocation of High Mobility Group Box 1 (HMGB1) from the nucleus to the extracellular space has been observed in epilepsy patients and experimental animal models. This study aimed to investigate the relationship between serum HMGB1 levels and cognitive function in epilepsy patients. Methods: This cross-sectional observational study involved 45 epilepsy patients. Cognitive function was assessed using the Indonesian version of the Montreal Cognitive Assessment (MoCA-Ina), and serum HMGB1 levels were measured using the ELISA technique. The relationship between cognitive function and HMGB1 levels was analyzed using the Kruskal-Wallis test, with a significance level set at p < 0.05. Results: The mean age of the participants was 28.5 years, with a higher proportion of females. The mean serum HMGB1 level was 22.6 ng/ml. No significant relationship was found between serum HMGB1 levels and cognitive function in epilepsy patients (p = 0.188). Conclusion: Serum HMGB1 protein levels were not associated with cognitive function in this sample of epilepsy patients.
Chemotherapy-Induced Cognitive Impairment and Neuroaxonal Damage: Investigating the Role of Serum Neurofilament Light Chain Husni Minanda Fikri; Syafrita, Yuliarni; Lydia Susanti; Syarif Indra; Restu Susanti; Reno Bestari
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 6 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i6.1319

Abstract

Background: Chemotherapy-induced cognitive impairment (CICI), colloquially termed "chemobrain," represents a significant challenge for cancer survivors, potentially affecting up to 85% of patients undergoing treatment. Diagnosis often relies on neuropsychological testing and imaging, which may lack sensitivity for early detection or reflect chronic changes. Neurofilament light chain (NfL), a neuronal structural protein released into biofluids upon neuroaxonal damage, emerges as a promising biomarker. This study investigated the relationship between serum NfL levels and the degree of cognitive impairment in patients receiving chemotherapy. Methods: An observational, cross-sectional study was conducted involving 50 cancer patients undergoing chemotherapy at Dr. M. Djamil General Hospital Padang between October and December 2024. Cognitive function was assessed using the Montreal Cognitive Assessment Indonesian version (MoCA-Ina), and depression was screened using the Patient Health Questionnaire-9 (PHQ-9). Serum NfL levels were quantified using an Enzyme-Linked Immunosorbent Assay (ELISA) method. The Kruskal-Wallis test was employed to analyze the relationship between serum NfL levels and cognitive function status (normal, mild impairment, moderate-severe impairment). Results: Cognitive impairment (MoCA-Ina assessed) was identified in 41 (82%) of the 50 participants, with 30 (60%) exhibiting mild and 11 (22%) exhibiting moderate to severe impairment. The median serum NfL level across all subjects was 23.44 pg/ml (range: 13.81-68.71 pg/ml). A statistically significant relationship was observed between serum NfL levels and the presence and severity of cognitive impairment (p = 0.02). Median NfL levels progressively increased from the cognitively normal group (18.49 pg/ml) to the mild impairment group (23.5 pg/ml) and the moderate-severe impairment group (24.5 pg/ml). Post-hoc analysis revealed significant differences in NfL levels between the normal group and both the mild (p=0.03) and moderate-severe (p=0.01) impairment groups. Conclusion: This study demonstrated a significant positive association between serum NfL levels and the presence and severity of cognitive impairment in cancer patients undergoing chemotherapy. These findings support the potential utility of serum NfL as an accessible biomarker for detecting chemotherapy-associated neuroaxonal damage and concomitant cognitive decline.
CORRELATION BETWEEN NEURON-SPECIFIC ENOLASE (NSE) SERUM LEVEL AND TRAUMATIC BRAIN INJURY SEVERITY Pitra, Dian Ayu Hamama; Syafrita, Yuliarni; Susanti, Rika; Rita, Rauza Sukma
Nusantara Hasana Journal Vol. 5 No. 1 (2025): Nusantara Hasana Journal, June 2025
Publisher : Yayasan Nusantara Hasana Berdikari

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59003/nhj.v5i1.1498

Abstract

Traumatic brain injuries (TBIs) are a health and socio-economic problem worldwide, both in low- and high-income countries, that affects all age groups. Computed Tomography (CT) is a diagnostic modality that can be used to assess brain damage. However, there are some limitations in the use of CT in TBIs. Therefore, biomarkers are expected to be a solution to identify brain injuries. Neuron-Specific Enolase (NSE) is a more practical and cheaper alternative. It does not require patient mobilization, especially for patients with severe TBIs, to accompany clinical examinations and CT. Methods: A cross-sectional design was used to determine the correlation between Neuron Specific Enolase (NSE) serum levels and the severity of TBIs at RSUP Dr. M. Djamil, Padang. Results: The study found that most patients were 23 men (76.7%), consisting of adults (40.0%). The majority of patients had mild traumatic brain injury (GCS 13-15) in 18 people (60.0%). The cut-off point for serum NSE was 6.6 ng/ml using the ROC curve. There was a negative correlation between serum NSE levels and the severity of TBI (r=-0.211). Conclusion: The correlation of serum NSE levels with the severity of TBI was very weak.
Co-Authors Adang Bachtiar Afriyeni Sri Rahmi Alya Ramadhini Andi Fadilah Yusran Andy, Marfri Anggi Anugerah Basir ATTIYA ISTARINI Basjiruddin Ahmad Cintya Agreayu Dinata Darwin Amir Darwin Amir Darwin Amir, Darwin Dedi Sutia Dhiang Mulia Syofiadi Djong Hon Tjong Dwi Sri Rejeki Dwitya Elvira, Dwitya Elsi Rahmadhani Hardi Elvia Fataya Ennesta Asri Erdanela Setiawati Eva Chundrayetti Eva Decroli Fadel Muhammad Fadrian, Fadrian Fanny Adhy Putri Fitra Ermila Basri Gunawan Septa Dinata Haiga, Yuri Harun Harnavi Hauda El Rasyid Hendra Permana Husni Minanda Fikri Indra, Syarif Iqbal Al Rasyid Isnu Lucky Riandini Istiqomah Jabbar, Ridho Ahmad Karina Prasasti Helhid Kurniawan, Yoga Setia Lydia Susanti Lydia Susanti Lydia Susanti Lydia Susanti M Hasan Machfoed Marfri Andy Marliana, Lesti Meldayeni Busra Mubarak, M. Dzaky Muhammad Farhan Khadaffi Mustafa Noer Nela Novita Sari Netti Suharti Nora Fitri Nora Fitri Novi Yudia Nur Indrawati Lipoeto Nur Indrawaty Lipoeto Nurhayati Nurhayati Nurvalinda, Nurvalinda Pitra, Dian Ayu Hamama Putri, Fanny Adhy Rahmi Ulfa Rahmi Ulfa Rasyid, Hauda El Ratna D Siregar Rauza Sukma Rita Reno Bestari Reno Bestari Reno Bestari Restu Susanti Rika Susanti Rika Susanti Rini Gusya Liza, Rini Gusya Rizanda Machmud Rizki Muhammad Rananda RR. Ella Evrita Hestiandari Russilawati, Russilawati Salmiah Agus Susila Sastri Susila Sastri Sutia, Dedi Syahrul, Muhammad Zulfadli Syarif Indra Syarif Indra Syarif Indra Trya Mia Intani Widia Rahmawati Yantri Maputra Yanwirasti Yanwirasti Yaumi Faiza Yoga Setia Kurniawan Yulia Trisna